RNAi is well-positioned to better address the unmet medical needs of obesity and metabolic related disorders, due to its potential advantages as a new drug modality in safety, efficacy and durability. SanegeneBio is developing differentiated extrahepatic tissue-selective delivery technologies using our LEAD™ (Ligand and Enhancer Assisted Delivery) platform, aiming to bring innovative treatments for obesity beyond GLP-1 RAs.
Marc Abrams, our CTO and Head of US Operations, delivered a speech at OPT Congress 2025 on March 12th. In this presentation, he shared SanegeneBio’s updated clinical data of our leading program, as well as great progress in extrahepatic delivery to adipose tissues, based on which the SGB-ALK7 program for obesity treatment is well on track for IND in early 2026.
